Mathieu Kerneis

Title: The Innovative Contributions of Mathieu Kerneis

Introduction

Mathieu Kerneis is a notable inventor based in Paris, France. He has made significant contributions to the field of medicine, particularly in the treatment of adverse events induced by immune checkpoint inhibitors. His work is characterized by a commitment to improving patient outcomes through innovative solutions.

Latest Patents

Mathieu Kerneis holds a patent for a method aimed at treating checkpoint inhibitors induced adverse events. The invention relates to the use of CTLA4 agonist for treating or preventing adverse events in patients treated with an immune checkpoint inhibitor. This patent highlights his dedication to advancing medical treatments and addressing critical challenges in patient care. He has 1 patent to his name.

Career Highlights

Throughout his career, Mathieu has worked with prestigious institutions such as Sorbonne Université and Assistance Publique-Hôpitaux de Paris. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Mathieu has collaborated with notable professionals, including Javid Moslehi and Yves Allenbach. These partnerships have enriched his work and expanded the impact of his inventions.

Conclusion

Mathieu Kerneis exemplifies the spirit of innovation in the medical field. His contributions, particularly in the treatment of adverse events related to immune checkpoint inhibitors, demonstrate his commitment to enhancing patient care. His work continues to inspire advancements in medical research and treatment methodologies.